Copyright
©The Author(s) 2025.
World J Gastroenterol. Jan 7, 2025; 31(1): 101463
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101463
Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.101463
Characteristics | First-line treatment, n = 250 | Rescue treatment, n = 130 | P value |
Age in years | 65.3 ± 4.4 | 65.1 ± 3.6 | 0.6000 |
Range | 60-82 | 60-76 | |
Sex as M/F | 106/144 | 60/70 | 0.5500 |
Body weight in kg | 65.5 ± 11.3 | 65.8 ± 10.8 | 0.8000 |
BMI in kg/m2 | 24.0 ± 3.4 | 23.7 ± 2.9 | 0.3700 |
Cigarette smoking | 31 (12.4) | 15 (11.5) | 0.9300 |
Alcohol drinking | 35 (14.0) | 27 (20.8) | 0.1200 |
Family history of gastric cancer | 15 (6.0) | 15 (11.5) | 0.0900 |
Endoscopy diagnosis | |||
Gastritis | 193 (77.2) | 97 (77.2) | 0.6600 |
CSG | 108 (43.2) | 32 (24.6) | 0.0006c |
CAG | 85 (34.0) | 65 (50.0) | 0.0035b |
Peptic ulcer | 51 (20.4) | 27 (20.8) | 1.0000 |
Gastric ulcer | 14 (5.6) | 11 (4.4) | 0.4000 |
Duodenal ulcer | 27 (10.8) | 16 (6.4) | 0.7900 |
Complex (gastric and duodenal) ulcer | 10 (4.0) | 0 (0.0) | 0.0180a |
Gastric cancer | 1 (0.4) | 1 (0.8) | 1.0000 |
MALToma | 3 (1.2) | 0 (0.0) | 0.5500 |
Gastric hyperplastic polyp | 2 (0.8) | 5 (3.8) | 0.0490a |
Combined diseases | 1.8 ± 1.4 | 1.8 ± 1.4 | 0.9020 |
0 | 53 (21.2) | 26 (20.0) | 0.8900 |
1 | 61 (24.4) | 34 (26.1) | 0.8000 |
2 | 64 (25.6) | 35 (26.9) | 0.8800 |
≥ 3 | 72 (28.8) | 35 (16.9) | 0.7900 |
Combined medicine | 1.3 ± 1.6 | 1.5 ± 1.7 | 0.3400 |
0 | 99 (39.6) | 45 (34.6) | 0.4000 |
1 | 59 (23.6) | 36 (27.7) | 0.4500 |
2 | 40 (16.0) | 17 (13.1) | 0.5400 |
≥ 3 | 52 (20.8) | 32 (24.6) | 0.4700 |
Comorbidity | |||
Hypertension | 89 (35.6) | 49 (37.7) | 0.7700 |
Diabetes mellitus | 45 (18.0) | 20 (15.4) | 0.6200 |
Hyperlipidemia | 88 (35.2) | 33 (25.4) | 0.0700 |
Heart disease | 32 (12.8) | 15 (11.5) | 0.8500 |
Lung disease | 10 (4.0) | 5 (3.8) | 1.0000 |
Liver disease | 28 (11.2) | 12 (9.2) | 0.6800 |
Renal disease | 13 (5.2) | 7 (5.4) | 1.0000 |
Cerebrovascular disease | 10 (4.0) | 7 (5.4) | 0.6000 |
Autoimmune disease | 24 (9.6) | 9 (6.9) | 0.4500 |
Hypersensitivity disease | 4 (1.6) | 4 (3.1) | 0.4500 |
Other malignant tumor | 25 (10.0) | 19 (14.6) | 0.2400 |
Adherence | 247 (98.8) | 128 (98.5) | 1.0000 |
Adverse events | 23 (9.2); 95%CI: 6.2%-13.4% | 13 (10.0); 95%CI: 4.8%-15.2% | 1.0000 |
Eradication rate | 95.6% (239/250); 95%CI: 93.0%-98.1% | 89.2% (116/130); 95%CI: 83.9%-94.6% | 0.0300a |
- Citation: Gao W, Li JW, Ye H, Zhang XZ, Liu JX, Cheng H. Real-world evidence on the efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori treatment in elderly patients. World J Gastroenterol 2025; 31(1): 101463
- URL: https://www.wjgnet.com/1007-9327/full/v31/i1/101463.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i1.101463